United Kingdom - English - myHealthbox

zentiva - hydroxychloroquine sulfate - film-coated tablets - 200mg - treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight in adults; treatment of juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus erythematosus in children

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets, usp are indicated for the treatment of uncomplicated malaria due to p. falciparum , p. malariae , p. ovale , and p. vivax .   hydroxychloroquine sulfate tablets, usp are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria   - hydroxychloroquine sulfate tablets, usp are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets, usp are not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (seeclinical pharmacology – microbiology) . hydroxychloroquine sulfate tablets, usp are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets, usp are not recommended for malaria prophylaxis in geographic areas where chloroquine

Malta - English - Medicines Authority

ipca produtos farmaceuticos unipessoal lda rua jose nogueira vaz no 8b 2625-099 povoa de santa iria , portugal - film-coated tablet - hydroxychloroquine sulfate 200 mg - antiprotozoals

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: colloidal anhydrous silica; pregelatinised maize starch; magnesium stearate; hypromellose; polysorbate 80; calcium hydrogen phosphate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: colloidal anhydrous silica; calcium hydrogen phosphate; hypromellose; polysorbate 80; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

United States - English - NLM (National Library of Medicine)

cardinal health - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate 200 mg

United States - English - NLM (National Library of Medicine)

avkare, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate 200 mg

Malta - English - Medicines Authority

p & d pharmaceuticals limited 38 woolmer way, bordon hampshire gu35 9qf, united kingdom - hydroxychloroquine sulfate - film-coated tablet - hydroxychloroquine sulfate 200 mg - antiprotozoals

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets are indicated for the suppressive treatment and treatments of acute attacks of malaria due to plasmodium vivax , p. malariae , p. ovale , and susceptible strains of p. falciparum . it is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known hypersensitivity to 4-aminoquinoline compounds, and (3) for long-term therapy in children.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets, usp are indicated for the suppressive treatment and treatment of acute attacks of malaria due to plasmodium vivax , p. malariae , p. ovale , and susceptible strains of p. falciparum . hydroxychloroquine sulfate tablets, usp are also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known hypersensitivity to 4-aminoquinoline compounds, and (3) for long-term therapy in children.